Seattle-based startup Oisín Biotechnologies recently raised the first close of a $15 million Series A round. The company is focused on developing preclinical therapies to target aging-related diseases by eliminating unwanted fat cells and building muscle mass to address frailty. Oisin was founded in 2016 by Matthew Scholz, who also serves as the CEO of OncoSenX, a company that spun out of Oisín in 2018 and is dedicated to studying the treatment of solid tumors. John Lewis, the chief science officer, and Gary Hudson, the chairman, are also founding members of Oisín.
The funding round was led by AbbVie Ventures, indicating strong interest and support from investors in Oisín’s work. With the first close of the Series A round secured, the company now has the financial backing to continue its research and development efforts in the field of aging-related diseases. The focus on eliminating unwanted fat cells and boosting muscle mass could have significant implications for addressing frailty, a common issue associated with aging. Oisín’s innovative approach to targeting these aspects of aging could potentially lead to breakthrough treatments in the future.
Oisín Biotechnologies is at the forefront of developing cutting-edge therapies that aim to combat aging-related diseases. By targeting fat cells and muscle mass, the company is taking a unique approach to addressing frailty, a condition that affects many older individuals. With the support of investors like AbbVie Ventures, Oisín has the resources needed to advance its preclinical therapies and potentially revolutionize the field of aging research. The leadership team, including CEO Matthew Scholz, has a strong background in biotechnology and a proven track record of success in the industry.
The successful completion of the first close of the Series A round is a significant milestone for Oisín Biotechnologies. This initial funding will enable the company to further develop its promising therapies and move closer to bringing them to market. With a focus on addressing aging-related diseases, Oisín is poised to make a meaningful impact on the field of biotechnology and healthcare. By targeting fat cells and muscle mass, the company’s therapies have the potential to transform the way we approach aging and frailty.
Overall, Oisín Biotechnologies has solidified its position as a leading player in the biotechnology industry with its innovative approach to treating aging-related diseases. The completion of the first close of the Series A round demonstrates a strong vote of confidence from investors, highlighting the potential of Oisín’s therapies. With a talented leadership team and a clear focus on addressing frailty through the elimination of unwanted fat cells and the promotion of muscle mass, Oisín is well-positioned to make significant strides in the field of aging research. As the company continues to advance its preclinical therapies, the future looks bright for Oisín Biotechnologies and its mission to revolutionize the treatment of aging-related diseases.
